TARGINIQ Drug Patent Profile

When do Targiniq patents expire, and when can generic versions of Targiniq launch?

Targiniq is a drug marketed by Purdue Pharma Lp and is included in one NDA.

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this compound. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

Summary for TARGINIQ

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TARGINIQ

US Patents and Regulatory Information for TARGINIQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-001	Jul 23, 2014		DISCN	Yes	No
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-002	Jul 23, 2014		DISCN	Yes	No
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-003	Jul 23, 2014		DISCN	Yes	No

International Patents for TARGINIQ

See the table below for patents covering TARGINIQ around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2015155467	乱用防止制御放出オピオイド投薬形態 (ABUSE-RESISTANT CONTROLLED-RELEASE OPIOID DOSAGE FORM)
Hungary	E032656
Argentina	118531	PROCESO PARA DISMINUIR LA CANTIDAD DE 14-HIDROXICODEINONA EN CLORHIDRATO DE OXICODONA Y CLORHIDRATO DE OXICODONA QUE TIENE 14-HIDROXICODEINONA CON NIVEL INFERIOR A 100 PPM

Supplementary Protection Certificates for TARGINIQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
1685839	CA 2013 00052	Denmark		PRODUCT NAME: KOMBINATION AF OXYCODON SOM KOMPONENT A OG NALOXON SOM KOMPONENT B, HERUNDER OXYCODONHYDROCHLORID OG NALOXONHYDROCHLORIDDIHYDRAT; NAT. REG. NO/DATE: 43673, 43674 20081117; FIRST REG. NO/DATE: DE 64537.00.00, 64538.00.00, 64540.00.00, 64541.00.00 20060530
1685839	122013000082	Germany		PRODUCT NAME: KOMBINATION VON OXYCODON ALS KOMPONENTE A UND NALOXON ALS KOMPONENTE B IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 73083.00.00 73084.00.00 73085.00.00 73086.00.00 20060530

Investment Scenario and Fundamentals Analysis for TARGINIQ (NAD+)

Last updated: April 24, 2026

What is TARGINIQ and what is its commercial product scope?

TARGINIQ is the brand name for oxycodone/naloxone prolonged-release (PR) tablets. The product combines:

• Oxycodone (opioid analgesic)
• Naloxone (opioid antagonist) intended to reduce opioid-induced constipation effects while maintaining analgesia

TARGINIQ is marketed across multiple geographies where national reimbursement and controlled-substance regulations permit opioid PR products.

Core product positioning

• Drug class: Opioid analgesic with abuse-responsiveness/constipation-mitigation design via antagonist co-formulation
• Formulation: Prolonged-release tablet
• Clinical intent: Treatment of moderate to severe pain in patients who require sustained opioid exposure

How do the fundamentals map to patent and regulatory economics?

Investment value in opioid PR fixed-dose combinations is driven by four linked fundamentals:

1. Regulatory and label durability (including any label expansions around dosing, patient subsets, and long-term use)
2. Supply continuity (manufacturing scale, regulatory inspections, and batch release stability)
3. Exclusivity runway (patents and data protection)
4. Reimbursement and prescribing access (health technology assessment outcomes, formulary placement, and tender dynamics)

TARGINIQ’s economic model depends on the persistence of:

• payer willingness to fund an opioid PR/antagonist combination at premium pricing versus opioid-only PR comparators
• clinician acceptance of the constipation-mitigation value proposition relative to competing fixed-dose PR products

What competitive set matters for TARGINIQ?

TARGINIQ competes in the opioid PR pain segment, with differentiation centered on the oxycodone/naloxone mechanism.

Competitive axes

• Mechanism differentiation: Oxycodone plus naloxone versus oxycodone-only PR or other opioid/antagonist combinations
• Formulation differentiation: Prolonged-release dosing convenience and titration economics
• Access differentiation: Formulary preference, step edits, and prior authorization patterns

Primary substitutes

• Oxycodone PR products (single-entity)
• Other opioid PR fixed-dose combinations where constipation management relies on add-on therapies rather than antagonist co-formulation

What is the core investment thesis by fundamentals?

A credible investment scenario typically hinges on whether the company holding TARGINIQ has:

• sufficient exclusivity duration to sustain pricing and market share
• continued physician access across key countries, including stable reimbursement
• defendable manufacturing and quality compliance to prevent distribution disruptions
• managed safety and regulatory risk given the class profile of opioids

Bull case fundamental drivers

• Expansion of treated patient segments within the label and guideline-aligned prescribing
• Sustained reimbursement coverage versus payer moves toward cheaper opioid alternatives plus symptom management
• Low disruption risk through manufacturing redundancy and regulatory track record

Bear case fundamental drivers

• Loss of reimbursement momentum due to cost containment or opioid utilization caps
• Patent expiry-driven erosion if generics/authorized equivalents enter at scale
• Safety scrutiny leading to tighter prescribing restrictions or altered risk management plans

What are the likely market dynamics that shape revenue?

Opioid PR markets behave differently from non-controlled chronic therapeutics because they face:

• tighter dispensing oversight
• payer scrutiny on total opioid burden
• periodic guideline updates that can change opioid choice architecture

Seasonality and utilization

Revenue is typically less dependent on seasonal demand than on:

• physician prescribing behavior
• regional enforcement changes affecting opioid dispensing
• formulary updates and tender cycles

Pricing mechanics

Pricing often depends on:

• health technology assessment outcomes
• relative cost-per-day compared with opioid-only PR options and add-on constipation regimens
• negotiated discounts tied to managed-care penetration

What does the patent and exclusivity framework mean for downside protection?

For a branded opioid PR combination like TARGINIQ, the investment protection layer is primarily:

• brand exclusivity (including patents on formulation, dosing, or method-of-use where enforceable)
• data and marketing exclusivity in each country
• regulatory exclusivity constraints that delay generic substitution

The practical implication for investors is that the valuation should be anchored to:

• time to meaningful generic/authorized entry in the largest reimbursement markets
• expected competitive intensity post-expiry (number of entrants, pricing pressure, tender rules)

What are the fundamental risk factors specific to oxycodone/naloxone PR?

Risk analysis focuses on clinical and regulatory realities of opioids.

Regulatory and safety

• opioid class boxed warnings and REMS-style risk control frameworks (where applicable)
• monitoring requirements for misuse, abuse, and diversion
• label restrictions that can tighten prescribing eligibility

Commercial and enforcement

• potential payer restrictions targeting opioid utilization
• substitution risk if generics appear that replicate the dosing strength and PR profile

Operational

• controlled-substance supply chain compliance
• batch release delays in heavily regulated jurisdictions

How should an investor structure the scenario analysis?

A scenario model for TARGINIQ should be built around three decision points: exclusivity runway, reimbursement durability, and competitive substitution timing.

Scenario tree (investment-relevant)

1. Base case

   • formulary stability holds in major markets
   • competitive pressure increases gradually
   • pricing declines in line with class dynamics

2. Downside case

   • reimbursement downgrades trigger steeper net price erosion
   • faster-than-expected substitution after any exclusivity event
   • increased restrictions reduce eligible patient base

3. Upside case

   • payer and guideline alignment supports sustained uptake
   • limited competitive substitution due to regulatory or access barriers
   • net pricing stabilizes longer than expected

Key fundamentals checklist for diligence

Use these categories to validate thesis quality before committing capital:

Market access

• formulary coverage and step-edit requirements
• prior authorization intensity for opioid PR combination therapies
• tender participation and pricing concessions

Regulatory trajectory

• label expansions or restriction changes
• safety communications and risk management program updates
• manufacturing site inspection outcomes and batch availability

Competitive threat monitoring

• mapping of potential generic entry triggers by jurisdiction
• competitor movement from oxycodone-only PR to opioid/antagonist combos
• real-world switching rates at the pharmacy and prescriber level

What would materially move valuation for TARGINIQ?

In a branded opioid PR combination, valuation can shift due to:

• a single-country reimbursement loss in a top-earning market
• accelerated generic entry in key jurisdictions
• a label update that materially changes eligible dosing or patient subsets
• supply disruptions that lead to backorders and loss of prescriber habit formation

Where is the “time value” of money most sensitive?

Sensitivity usually concentrates on:

• timing of exclusivity end dates in top geographies
• the rate of net price declines after generic or authorized entry
• the lag between payer decision and market behavior (prescriber switching inertia)

Key Takeaways

• TARGINIQ is oxycodone/naloxone prolonged-release positioned to reduce constipation burden versus opioid-only PR approaches while maintaining opioid analgesia.
• Investment fundamentals hinge on exclusivity runway, reimbursement durability, and competitive substitution timing across major markets.
• Downside risk concentrates on generic entry and payer cost containment that forces faster net price erosion and patient switching.
• Upside requires stable access plus slower competitive substitution, not just trial-level efficacy claims.
• Material valuation moves typically come from reimbursement outcomes, label/risk management changes, and manufacturing/supply continuity in top-earning jurisdictions.

FAQs

1. Is TARGINIQ an opioid-only product?
   No. It is a fixed-dose combination of oxycodone (opioid) and naloxone (antagonist) in prolonged-release form.

2. What is the main commercial differentiator for TARGINIQ?
   The combination design aims to mitigate opioid-induced constipation while sustaining analgesia, which can support payer and prescriber adoption versus oxycodone-only PR.

3. What drives revenue most for an opioid PR combination brand?
   Reimbursement access and net pricing plus persistence of prescribing behavior under controlled-substance constraints.

4. What is the most important downside risk category?
   Exclusivity loss and generic/authorized substitution, followed by steeper net price declines and patient switching.

5. What operational factor can hit earnings quickly?
   Any supply disruption (controlled-substance compliance, manufacturing downtime, or batch release delays) that forces therapy interruption and breaks prescriber habit.

References

[1] No cited sources were provided in the request.